ClinicalTrials.gg
CompletedNCT04410406Updated Jan 29, 2026Results posted

Moxidectin for LF, Cote d'Ivoire (DOLF)

A Phase 3 interventional study of Ivermectin and Diethylcarbamazine in Lymphatic Filariasis, sponsored by Washington University School of Medicine. Completed at 1 site in Côte d’Ivoire. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-29.

Sponsored by Washington University School of Medicine · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
164
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The purpose of this study is to determine whether moxidectin (Mox) will be more effective than ivermectin (IVM) when used in single-dose combination therapies for lymphatic filariasis (LF).

Read the detailed description

This study will test the hypothesis that Moxidectin combination therapies are superior to ivermectin combination therapies for achieving sustained clearance of W. bancrofti microfilaremia.

This trial is designed as single-site, Phase III, randomized, open-label, masked-observer superiority trial with four treatment arms: ivermectin + albendazole (IA), moxidectin + albendazole (MoxA), ivermectin + diethylcarbamazine + albendazole (IDA), and moxidectin + diethylcarbamazine + albendazole (MoxDA). The primary endpoint is the proportion of participants achieving complete clearance of microfilaremia at 12 months (IA vs. MoxA comparison) or 24 months (IDA vs. MoxDA comparison). Block randomization by gender will be used to assign treatment arms.

The first 48 participants (12 each arm) will be treated at Agboville Hospital in Cote d'Ivoire at the Centre de Recherche de Filariose with inpatient AE monitoring and collection of post-treatment plasma drug levels (Part 1). For Part 1, active AE surveillance will be conducted in the hospital on days 1, 2, and 3, post-treatment, and in the participant's village of residence on day 7 post-treatment and passive surveillance will be conducted by trained village health workers on days 4-6. An interim safety analysis will take place after Part 1. If no safety concerns are identified, the remainder of the participants will be treated in their home villages, with active AE monitoring on days 1 and 2 post-treatment (Part 2) with passive surveillance by trained village health workers on days 3-7. Any participant in either Part 1 or Part 2 experiencing AEs of grade 2 or higher will be followed until adverse event (AE) severity falls below grade 2. Follow-up assessments for efficacy of treatments for all participants (Parts 1 and 2) will be conducted at 6, 12, 24, and 36 months.

The study includes both safety and efficacy analyses. The safety assessment (Part 1 only) ends 7 days after treatment (unless AEs remain grade 2 or higher). The efficacy assessment (Parts 1 and 2 combined) ends when participants are retested for filarial infection 36 months post-treatment. Participants in the IA arm will receive IA annually (standard of care). Participants in the other arms will receive the assigned treatment at baseline; those found to be microfilaremic at 24 months post-treatment will be retreated with the same treatment received at baseline. If clearance of microfilariae (Mf) at 12 months in the IA arm is superior to Mf clearance in the MoxA arm, the MoxA group will be switched to annual IA treatment.

The study design does not currently include stratification, nor do any sub-studies. However, the study may stratify based on pre-treatment Mf levels if high variability among pre-screening Mf counts is observed.

02

Conditions studied

  • Lymphatic Filariasis

Keywords

  • moxidectin
  • ivermectin
03

In context

Elephantiasis, Filarial

42 studies on the registry are indexed under Elephantiasis, Filarial; 5 are open to participants now.

This study's enrollment of 164 is below the median of 1,000 across 27 interventional studies indexed under Elephantiasis, Filarial.

Browse Elephantiasis, Filarial studies →

Lead sponsor

Washington University School of Medicine is the lead sponsor of 1,806 studies on the registry; 271 are open to participants now.

Of its 329 completed or terminated interventional studies of FDA-regulated products, 216 (66%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of signed and dated form
  • Male or female, aged 18-70 years
  • In good general health as evidenced by medical history
  • Peripheral night blood W. bancrofti Mf levels ≥40 Mf/mL
  • No history of taking antifilarial medications in past 12 months
  • Resident of the study area with no plans to change residence in the next 36 months
  • For women of , willing to use appropriate method of for one month following each treatment

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or currently breastfeeding
  • Known allergic reactions to any of the study medications
  • Evidence of severe or systemic comorbidities (aside from features of filarial disease), as judged by the principal investigator
  • Baseline biochemical abnormalities, as indicated by , ALT, or creatinine > 2 times the
  • Evidence of urinary tract infection as indicated by 3+ nitrites on dipstick (individuals with 1+ or 2+ nitrites will not be excluded) or underlying chronic kidney disease as indicated by 3+ protein or 3+ blood on urine dipstick exam
  • \< 7 gm/dL (any such individuals will be referred to the local health center for evaluation and treatment)
  • Positive skin snip for onchocerciasis
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
164 participants (actual)

Study arms

  • Active comparator
    IA (Ivermectin + Albendazole)

    Participants will receive one oral dose of Ivermectin (IVM) 200 µg/kg + Albendazole (ABZ) 400 mg (IA) annually for 24 months.

    Drug: Ivermectin · Drug: Albendazole

  • Active comparator
    MoxA (Moxidectin + Albendazole)

    Participants will receive one oral dose of Mox 8 mg + ABZ 400 mg. Participants who are Mf positive at 24 months will be retreated with MoxA at the same dosage.

    Drug: Albendazole · Drug: Moxidectin

  • Active comparator
    IDA (Ivermectin + Diethylcarbamazine + Albendazole)

    Participants will receive one oral dose of IVM 200 µg/kg + Diethylcarbamazine (DEC) 6mg/kg + ABZ 400 mg. Participants who are Mf positive at 24 months will be retreated with IDA at the same dosage.

    Drug: Ivermectin · Drug: Diethylcarbamazine · Drug: Albendazole

  • Active comparator
    MoxDA (Moxidectin + Diethylcarbamazine + Albendazole)

    Participants will receive one oral dose of Mox 8 mg + DEC 6mg/kg + ABZ 400 mg. Participants who are Mf positive at 24 months will be retreated with MoxDA at the same dosage.

    Drug: Diethylcarbamazine · Drug: Albendazole · Drug: Moxidectin

Interventions

06

What researchers measure

Primary outcomes

  1. Clearance of Microfilaremia (IA vs. MoxA)

    The proportion of participants in IA and MoxA study arms with complete clearance of W. bancrofti microfilaremia at 12 months after treatment.

    Time frame: 12 months

  2. Clearance of Microfilaremia (IDA vs. MoxDA)

    The proportion of participants in IDA and MoxDA study arms with complete clearance of W. bancrofti microfilaremia at 24 months after treatment.

    Time frame: 24 months

Secondary outcomes

  1. Clearance of Microfilaremia

    The proportion of participants in each study arm with complete clearance of W. bancrofti microfilaremia at 6, 12, 24, \& 36 months after treatment.

    Time frame: 6, 12, 24, & 36 months

  2. Change in Mf Counts

    Change in microfilariae counts (relative to baseline) at12 \& 24 months

    Time frame: Assessed at Baseline, 6, 12, & 24 months; Reported at 12 and 24 months

  3. Reduction in Circulating Filarial Antigen (CFA) Counts

    Reduction in circulating filarial antigen (CFA) counts (relative to baseline) at 12 \& 24 months

    Time frame: Assessed at Baseline, 6, 12, & 24 months; 12 and 24 months reported

  4. Inactivation of Adult Worm Nests in Male Participants Only

    Inactivation of adult worm nests as assessed by scrotal ultrasound at 6, 12, and 24 months after treatment in male participants only

    Time frame: 6, 12, & 24 months

  5. Frequency and Severity of AEs

    Frequency and severity of AEs during the first 7 days after treatment.

    Time frame: From baseline treatment to 7 days post-treatment

  6. Plasma Levels of Drugs/Metabolites Post Treatment

    Noncompartmental pharmacokinetic analyses of DEC, ABZ, ABZSO, ABZSO2, IVM and Mox concentrations will be conducted using WinNonlin (Pharsight Corporation; Cary, North Carolina, USA). Drug plasma concentrations and computed pharmacokinetic parameters will be listed by subject and summarized by drug or metabolite (geometric mean with coefficient of variation, arithmetic mean with standard deviation, minimum, maximum, number of observations). Individual and geometric mean (by time) concentrations versus time will be plotted for each treatment group on both linear and natural logarithm scales.

    Time frame: Baseline, 2, 3, 4, 6, 12, 24, & 48 hours post-treatment

07

Results

Posted Jan 29, 2026

Participant flow

Participant flow — Overall Study
MilestoneIA (Ivermectin + Albendazole)MoxA (Moxidectin + Albendazole)IDA (Ivermectin + Diethylcarbamazine + Albendazole)MoxDA (Moxidectin + Diethylcarbamazine + Albendazole)
Started41404142
Completed25162223
Not completed16241919

Outcome measures

PrimaryClearance of Microfilaremia (IA vs. MoxA)

The proportion of participants in IA and MoxA study arms with complete clearance of W. bancrofti microfilaremia at 12 months after treatment.

Time frame:
12 months
Reported as:
Count of participants · Participants
Clearance of Microfilaremia (IA vs. MoxA)
ParticipantsIA (Ivermectin + Albendazole)MoxA (Moxidectin + Albendazole)IDA (Ivermectin + Diethylcarbamazine + Albendazole)MoxDA (Moxidectin + Diethylcarbamazine + Albendazole)
Clearance of Microfilaremia (IA vs. MoxA)8182427
PrimaryClearance of Microfilaremia (IDA vs. MoxDA)

The proportion of participants in IDA and MoxDA study arms with complete clearance of W. bancrofti microfilaremia at 24 months after treatment.

Time frame:
24 months
Reported as:
Count of participants · Participants
Clearance of Microfilaremia (IDA vs. MoxDA)
ParticipantsIA (Ivermectin + Albendazole)MoxA (Moxidectin + Albendazole)IDA (Ivermectin + Diethylcarbamazine + Albendazole)MoxDA (Moxidectin + Diethylcarbamazine + Albendazole)
Clearance of Microfilaremia (IDA vs. MoxDA)13142021
SecondaryClearance of Microfilaremia

The proportion of participants in each study arm with complete clearance of W. bancrofti microfilaremia at 6, 12, 24, \& 36 months after treatment.

Time frame:
6, 12, 24, & 36 months
Reported as:
Count of participants · Participants
Clearance of Microfilaremia
ParticipantsIA (Ivermectin + Albendazole)MoxA (Moxidectin + Albendazole)IDA (Ivermectin + Diethylcarbamazine + Albendazole)MoxDA (Moxidectin + Diethylcarbamazine + Albendazole)
6 months8152024
12 months8182427
24 months13142021
36 months22203032
SecondaryChange in Mf Counts

Change in microfilariae counts (relative to baseline) at12 \& 24 months

Time frame:
Assessed at Baseline, 6, 12, & 24 months; Reported at 12 and 24 months
Reported as:
Mean · Mf/mL
Change in Mf Counts
Mf/mLIA (Ivermectin + Albendazole)MoxA (Moxidectin + Albendazole)IDA (Ivermectin + Diethylcarbamazine + Albendazole)MoxDA (Moxidectin + Diethylcarbamazine + Albendazole)
12 Months20.70 (12.10 to 35.40)0.48 (0.07 to 3.10)1.30 (0.46 to 3.40)0.05 (0.01 to 0.42)
24 Months8.10 (3.10 to 21.40)2.50 (0.57 to 10.60)2.00 (0.32 to 12.70)0.70 (0.12 to 4.20)
SecondaryReduction in Circulating Filarial Antigen (CFA) Counts

Reduction in circulating filarial antigen (CFA) counts (relative to baseline) at 12 \& 24 months

Time frame:
Assessed at Baseline, 6, 12, & 24 months; 12 and 24 months reported
Reported as:
Geometric mean · ng/mL
Reduction in Circulating Filarial Antigen (CFA) Counts
ng/mLIA (Ivermectin + Albendazole)MoxA (Moxidectin + Albendazole)IDA (Ivermectin + Diethylcarbamazine + Albendazole)MoxDA (Moxidectin + Diethylcarbamazine + Albendazole)
12 Months21.70 (13.60 to 34.60)12.50 (7.30 to 21.40)10.30 (6.60 to 16.20)7.80 (4.80 to 12.60)
24 Months12.16 (7.53 to 19.65)6.38 (3.7 to 11.01)5.14 (3.16 to 8.69)4.76 (2.89 to 7.84)
SecondaryInactivation of Adult Worm Nests in Male Participants Only

Inactivation of adult worm nests as assessed by scrotal ultrasound at 6, 12, and 24 months after treatment in male participants only

Time frame:
6, 12, & 24 months
Reported as:
Count of participants · Participants
Inactivation of Adult Worm Nests in Male Participants Only
ParticipantsIA (Ivermectin + Albendazole)MoxA (Moxidectin + Albendazole)IDA (Ivermectin + Diethylcarbamazine + Albendazole)MoxDA (Moxidectin + Diethylcarbamazine + Albendazole)
12 Months171010
24 Months48712
SecondaryFrequency and Severity of AEs

Frequency and severity of AEs during the first 7 days after treatment.

Time frame:
From baseline treatment to 7 days post-treatment
Reported as:
Count of participants · Participants
Frequency and Severity of AEs
ParticipantsIA (Ivermectin + Albendazole)MoxA (Moxidectin + Albendazole)IDA (Ivermectin + Diethylcarbamazine + Albendazole)MoxDA (Moxidectin + Diethylcarbamazine + Albendazole)
Frequency and Severity of AEs22241815
SecondaryPlasma Levels of Drugs/Metabolites Post Treatment

Noncompartmental pharmacokinetic analyses of DEC, ABZ, ABZSO, ABZSO2, IVM and Mox concentrations will be conducted using WinNonlin (Pharsight Corporation; Cary, North Carolina, USA). Drug plasma concentrations and computed pharmacokinetic parameters will be listed by subject and summarized by drug or metabolite (geometric mean with coefficient of variation, arithmetic mean with standard deviation, minimum, maximum, number of observations). Individual and geometric mean (by time) concentrations versus time will be plotted for each treatment group on both linear and natural logarithm scales.

Time frame:
Baseline, 2, 3, 4, 6, 12, 24, & 48 hours post-treatment
Reported as:
Mean · ng*hr/mL
Plasma Levels of Drugs/Metabolites Post Treatment
ng*hr/mLIA (Ivermectin + Albendazole)MoxA (Moxidectin + Albendazole)IDA (Ivermectin + Diethylcarbamazine + Albendazole)MoxDA (Moxidectin + Diethylcarbamazine + Albendazole)
ALB116.2 (10 to 686.3)172.1 (8 to 648.7)124.2 (9.9 to 366.2)82.4 (12.9 to 386.6)
ALB-OX3302.3 (1355.5 to 11146.8)4078.9 (897.4 to 5738.5)3512.5 (1264.8 to 9680.3)2595.8 (897.4 to 5738.5)
ALB-ON187.3 (43.2 to 593.9)300.8 (89.2 to 775)217.1 (79.5 to 613.5)174 (89.4 to 466.2)
DEC——21308.2 (11177.4 to 28869.3)19544.9 (12412.9 to 28740.7)
IVM1505.1 (606.5 to 3318.4)—1690.9 (885.5 to 3222.2)—
MOX—2530.8 (549.2 to 5933.8)—2653.2 (993.5 to 7507.8)

Adverse events

Collected over Active adverse event monitoring took place from treatment to 7 days post-treatment. Passive adverse event monitoring continued through 36-months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IA (Ivermectin + Albendazole)0/41 (0%)0/41 (0%)22/41 (53.7%)
MoxA (Moxidectin + Albendazole)2/40 (5%)2/40 (5%)24/40 (60%)
IDA (Ivermectin + Diethylcarbamazine + Albendazole)2/41 (4.9%)2/41 (4.9%)18/41 (43.9%)
MoxDA (Moxidectin + Diethylcarbamazine + Albendazole)0/42 (0%)0/42 (0%)15/42 (35.7%)
Most frequent serious events
Most frequent serious events
EventIA (Ivermectin + Albendazole)MoxA (Moxidectin + Albendazole)IDA (Ivermectin + Diethylcarbamazine + Albendazole)MoxDA (Moxidectin + Diethylcarbamazine + Albendazole)
DeathGeneral disorders0/411/402/410/42
SeizureGeneral disorders0/411/400/410/42
Most frequent other events
Showing 10 of 14
Most frequent other events
EventIA (Ivermectin + Albendazole)MoxA (Moxidectin + Albendazole)IDA (Ivermectin + Diethylcarbamazine + Albendazole)MoxDA (Moxidectin + Diethylcarbamazine + Albendazole)
Muscle or Joint PainGeneral disorders5/4111/405/415/42
HeadacheGeneral disorders9/414/403/415/42
Itching SkinGeneral disorders2/417/400/412/42
Abdominal PainGastrointestinal disorders7/412/404/412/42
DiarrheaGeneral disorders5/413/403/414/42
Dizziness, giddiness, or faintingGeneral disorders5/411/401/414/42
NauseaGeneral disorders0/410/403/411/42
Testicular or Scrotal PainGeneral disorders0/410/403/413/42
OtherGeneral disorders0/410/403/411/42
FatigueGeneral disorders1/412/400/411/42

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)IA (Ivermectin + Albendazole)MoxA (Moxidectin + Albendazole)IDA (Ivermectin + Diethylcarbamazine + Albendazole)MoxDA (Moxidectin + Diethylcarbamazine + Albendazole)Total
<=18 years00000
Between 18 and 65 years29223230113
>=65 years00000
Age, Continuous
Age, Continuous(years)IA (Ivermectin + Albendazole)MoxA (Moxidectin + Albendazole)IDA (Ivermectin + Diethylcarbamazine + Albendazole)MoxDA (Moxidectin + Diethylcarbamazine + Albendazole)Total
Mean34.6 ± 10.637.3 ± 10.238.3 ± 11.939.7 ± 11.837 ± 11.2
Sex: Female, Male
Sex: Female, Male(Participants)IA (Ivermectin + Albendazole)MoxA (Moxidectin + Albendazole)IDA (Ivermectin + Diethylcarbamazine + Albendazole)MoxDA (Moxidectin + Diethylcarbamazine + Albendazole)Total
Female222410
Male27203026103
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)IA (Ivermectin + Albendazole)MoxA (Moxidectin + Albendazole)IDA (Ivermectin + Diethylcarbamazine + Albendazole)MoxDA (Moxidectin + Diethylcarbamazine + Albendazole)Total
Count of participants————0
Region of Enrollment
Region of Enrollment(participants)IA (Ivermectin + Albendazole)MoxA (Moxidectin + Albendazole)IDA (Ivermectin + Diethylcarbamazine + Albendazole)MoxDA (Moxidectin + Diethylcarbamazine + Albendazole)Total
Côte D'Ivoire29223230113
Blood microfilaria count, median (IQR)
Blood microfilaria count, median (IQR)(Mf/mL)IA (Ivermectin + Albendazole)MoxA (Moxidectin + Albendazole)IDA (Ivermectin + Diethylcarbamazine + Albendazole)MoxDA (Moxidectin + Diethylcarbamazine + Albendazole)Total
Median342 (147 to 595)134 (98 to 318)204.5 (94 to 510.5)191.5 (83 to 312)209 (98 to 408)
08

Study locations

1 site
  • Regional Hospital of Agboville, Southern Cote d'Ivoire
    Agboville, Côte d’Ivoire
09

References and documents

Publications

  • Opoku NO, Bakajika DK, Kanza EM, Howard H, Mambandu GL, Nyathirombo A, Nigo MM, Kasonia K, Masembe SL, Mumbere M, Kataliko K, Larbelee JP, Kpawor M, Bolay KM, Bolay F, Asare S, Attah SK, Olipoh G, Vaillant M, Halleux CM, Kuesel AC. Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial. Lancet. 2018 Oct 6;392(10154):1207-1216. doi: 10.1016/S0140-6736(17)32844-1. Epub 2018 Jan 18. PubMed 29361335 ↗
  • Ichimori K, King JD, Engels D, Yajima A, Mikhailov A, Lammie P, Ottesen EA. Global programme to eliminate lymphatic filariasis: the processes underlying programme success. PLoS Negl Trop Dis. 2014 Dec 11;8(12):e3328. doi: 10.1371/journal.pntd.0003328. eCollection 2014 Dec. No abstract available. PubMed 25502758 ↗
  • Ottesen EA, Duke BO, Karam M, Behbehani K. Strategies and tools for the control/elimination of lymphatic filariasis. Bull World Health Organ. 1997;75(6):491-503. PubMed 9509621 ↗
  • Ottesen EA. Lymphatic filariasis: Treatment, control and elimination. Adv Parasitol. 2006;61:395-441. doi: 10.1016/S0065-308X(05)61010-X. PubMed 16735170 ↗
  • Thomsen EK, Sanuku N, Baea M, Satofan S, Maki E, Lombore B, Schmidt MS, Siba PM, Weil GJ, Kazura JW, Fleckenstein LL, King CL. Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis. Clin Infect Dis. 2016 Feb 1;62(3):334-341. doi: 10.1093/cid/civ882. Epub 2015 Oct 20. PubMed 26486704 ↗
  • King CL, Suamani J, Sanuku N, Cheng YC, Satofan S, Mancuso B, Goss CW, Robinson LJ, Siba PM, Weil GJ, Kazura JW. A Trial of a Triple-Drug Treatment for Lymphatic Filariasis. N Engl J Med. 2018 Nov 8;379(19):1801-1810. doi: 10.1056/NEJMoa1706854. PubMed 30403937 ↗
  • Edi C, Bjerum CM, Ouattara AF, Chhonker YS, Penali LK, Meite A, Koudou BG, Weil GJ, King CL, Murry DJ. Pharmacokinetics, safety, and efficacy of a single co-administered dose of diethylcarbamazine, albendazole and ivermectin in adults with and without Wuchereria bancrofti infection in Cote d'Ivoire. PLoS Negl Trop Dis. 2019 May 20;13(5):e0007325. doi: 10.1371/journal.pntd.0007325. eCollection 2019 May. PubMed 31107869 ↗
  • Irvine MA, Stolk WA, Smith ME, Subramanian S, Singh BK, Weil GJ, Michael E, Hollingsworth TD. Effectiveness of a triple-drug regimen for global elimination of lymphatic filariasis: a modelling study. Lancet Infect Dis. 2017 Apr;17(4):451-458. doi: 10.1016/S1473-3099(16)30467-4. Epub 2016 Dec 22. PubMed 28012943 ↗
  • Kyelem D, Biswas G, Bockarie MJ, Bradley MH, El-Setouhy M, Fischer PU, Henderson RH, Kazura JW, Lammie PJ, Njenga SM, Ottesen EA, Ramaiah KD, Richards FO, Weil GJ, Williams SA. Determinants of success in national programs to eliminate lymphatic filariasis: a perspective identifying essential elements and research needs. Am J Trop Med Hyg. 2008 Oct;79(4):480-4. PubMed 18840733 ↗
  • Molyneux DH, Hopkins A, Bradley MH, Kelly-Hope LA. Multidimensional complexities of filariasis control in an era of large-scale mass drug administration programmes: a can of worms. Parasit Vectors. 2014 Aug 15;7:363. doi: 10.1186/1756-3305-7-363. PubMed 25128408 ↗
  • Horton J. Albendazole: a broad spectrum anthelminthic for treatment of individuals and populations. Curr Opin Infect Dis. 2002 Dec;15(6):599-608. doi: 10.1097/00001432-200212000-00008. PubMed 12821837 ↗
  • Horton J, Witt C, Ottesen EA, Lazdins JK, Addiss DG, Awadzi K, Beach MJ, Belizario VY, Dunyo SK, Espinel M, Gyapong JO, Hossain M, Ismail MM, Jayakody RL, Lammie PJ, Makunde W, Richard-Lenoble D, Selve B, Shenoy RK, Simonsen PE, Wamae CN, Weerasooriya MV. An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis. Parasitology. 2000;121 Suppl:S147-60. doi: 10.1017/s0031182000007423. PubMed 11386686 ↗
  • Kitzman D, Cheng KJ, Fleckenstein L. HPLC assay for albendazole and metabolites in human plasma for clinical pharmacokinetic studies. J Pharm Biomed Anal. 2002 Oct 15;30(3):801-13. doi: 10.1016/s0731-7085(02)00382-5. PubMed 12367706 ↗
  • Geary TG. Ivermectin 20 years on: maturation of a wonder drug. Trends Parasitol. 2005 Nov;21(11):530-2. doi: 10.1016/j.pt.2005.08.014. Epub 2005 Aug 26. PubMed 16126457 ↗
  • Moreno Y, Nabhan JF, Solomon J, Mackenzie CD, Geary TG. Ivermectin disrupts the function of the excretory-secretory apparatus in microfilariae of Brugia malayi. Proc Natl Acad Sci U S A. 2010 Nov 16;107(46):20120-5. doi: 10.1073/pnas.1011983107. Epub 2010 Nov 1. PubMed 21041637 ↗
  • Awadzi K, Edwards G, Opoku NO, Ardrey AE, Favager S, Addy ET, Attah SK, Yamuah LK, Quartey BT. The safety, tolerability and pharmacokinetics of levamisole alone, levamisole plus ivermectin, and levamisole plus albendazole, and their efficacy against Onchocerca volvulus. Ann Trop Med Parasitol. 2004 Sep;98(6):595-614. doi: 10.1179/000349804225021370. PubMed 15324466 ↗
  • Kitzman D, Wei SY, Fleckenstein L. Liquid chromatographic assay of ivermectin in human plasma for application to clinical pharmacokinetic studies. J Pharm Biomed Anal. 2006 Mar 3;40(4):1013-20. doi: 10.1016/j.jpba.2005.08.026. Epub 2005 Oct 19. PubMed 16242280 ↗
  • Awadzi K, Edwards G, Duke BO, Opoku NO, Attah SK, Addy ET, Ardrey AE, Quartey BT. The co-administration of ivermectin and albendazole--safety, pharmacokinetics and efficacy against Onchocerca volvulus. Ann Trop Med Parasitol. 2003 Mar;97(2):165-78. doi: 10.1179/000349803235001697. PubMed 12803872 ↗
  • Bolla S, Boinpally RR, Poondru S, Devaraj R, Jasti BR. Pharmacokinetics of diethylcarbamazine after single oral dose at two different times of day in human subjects. J Clin Pharmacol. 2002 Mar;42(3):327-31. doi: 10.1177/00912700222011247. PubMed 11865970 ↗
  • Geary TG, Woo K, McCarthy JS, Mackenzie CD, Horton J, Prichard RK, de Silva NR, Olliaro PL, Lazdins-Helds JK, Engels DA, Bundy DA. Unresolved issues in anthelmintic pharmacology for helminthiases of humans. Int J Parasitol. 2010 Jan;40(1):1-13. doi: 10.1016/j.ijpara.2009.11.001. Epub 2009 Nov 20. PubMed 19932111 ↗
  • McGarry HF, Plant LD, Taylor MJ. Diethylcarbamazine activity against Brugia malayi microfilariae is dependent on inducible nitric-oxide synthase and the cyclooxygenase pathway. Filaria J. 2005 Jun 2;4:4. doi: 10.1186/1475-2883-4-4. PubMed 15932636 ↗
  • Weil GJ, Bogus J, Christian M, Dubray C, Djuardi Y, Fischer PU, Goss CW, Hardy M, Jambulingam P, King CL, Kuttiat VS, Krishnamoorthy K, Laman M, Lemoine JF, O'Brian KK, Robinson LJ, Samuela J, Schechtman KB, Sircar A, Srividya A, Steer AC, Supali T, Subramanian S; DOLF IDA Safety Study Group. The safety of double- and triple-drug community mass drug administration for lymphatic filariasis: A multicenter, open-label, cluster-randomized study. PLoS Med. 2019 Jun 24;16(6):e1002839. doi: 10.1371/journal.pmed.1002839. eCollection 2019 Jun. PubMed 31233507 ↗
  • Budge PJ, Herbert C, Andersen BJ, Weil GJ. Adverse events following single dose treatment of lymphatic filariasis: Observations from a review of the literature. PLoS Negl Trop Dis. 2018 May 16;12(5):e0006454. doi: 10.1371/journal.pntd.0006454. eCollection 2018 May. PubMed 29768412 ↗
  • Weil GJ, Lammie PJ, Richards FO Jr, Eberhard ML. Changes in circulating parasite antigen levels after treatment of bancroftian filariasis with diethylcarbamazine and ivermectin. J Infect Dis. 1991 Oct;164(4):814-6. doi: 10.1093/infdis/164.4.814. PubMed 1894943 ↗
  • Chhonker YS, Sleightholm RL, Murry DJ. Bioanalytical method development and validation of moxidectin in plasma by LC-MS/MS: Application to in vitro metabolism. Biomed Chromatogr. 2019 Feb;33(2):e4389. doi: 10.1002/bmc.4389. Epub 2018 Oct 30. PubMed 30238696 ↗
  • Hertz MI, Nana-Djeunga H, Kamgno J, Jelil Njouendou A, Chawa Chunda V, Wanji S, Rush A, Fischer PU, Weil GJ, Budge PJ. Identification and characterization of Loa loa antigens responsible for cross-reactivity with rapid diagnostic tests for lymphatic filariasis. PLoS Negl Trop Dis. 2018 Nov 16;12(11):e0006963. doi: 10.1371/journal.pntd.0006963. eCollection 2018 Nov. PubMed 30444866 ↗
  • Koudou GB, Bjerum CM, Ouattara FA, Gabo TP, Goss CW, Lew D, Dje NN, King CL, Fischer PU, Weil GJ, Budge PJ. Moxidectin combination therapies for lymphatic filariasis: an open-label, observer-masked, randomised controlled trial. Lancet Infect Dis. 2025 Oct;25(10):1075-1083. doi: 10.1016/S1473-3099(25)00111-2. Epub 2025 May 6. PubMed 40345209 ↗
  • Bjerum CM, Koudou BG, Ouattara AF, Lew D, Goss CW, Gabo PT, King CL, Fischer PU, Weil GJ, Budge PJ. Safety and tolerability of moxidectin and ivermectin combination treatments for lymphatic filariasis in Cote d'Ivoire: A randomized controlled superiority study. PLoS Negl Trop Dis. 2023 Sep 18;17(9):e0011633. doi: 10.1371/journal.pntd.0011633. eCollection 2023 Sep. PubMed 37721964 ↗
  • Chhonker YS, Bjerum C, Bala V, Ouattara AF, Koudou BG, Gabo TP, Alshehri A, Meite A, Fischer PU, Weil GJ, King CL, Budge PJ, Murry DJ. Pharmacokinetics of Moxidectin combined with Albendazole or Albendazole plus Diethylcarbamazine for Bancroftian Filariasis. PLoS Negl Trop Dis. 2023 Aug 24;17(8):e0011567. doi: 10.1371/journal.pntd.0011567. eCollection 2023 Aug. PubMed 37616301 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified datasets used for published results will be shared publically through a journal or other open source data repository so that the broader scientific community can access it. Datasets used for published results will be shared publically through a journal or other open source data repository so that the broader scientific community can access it. Only de-identified data will be shared outside of the study team.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2020 to primary completion in Oct 2024, 49 months.

Results were first posted in Jan 2026, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2020
First posted
Jun 1, 2020
StartActual
Aug 20, 2020
Primary completionActual
Oct 1, 2024
CompletionActual
Oct 1, 2024
Results first posted
Jan 29, 2026
Last update
Jan 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04410406
Collaborators
Case Western Reserve University, Centre Suisse de Recherches Scientifiques en Cote d'Ivoire
Responsible party
Sponsor
First posted
Jun 1, 2020
Start date
Aug 20, 2020
Primary completion
Oct 1, 2024
Completion
Oct 1, 2024
Results posted
Jan 29, 2026
Last update
Jan 29, 2026

Study contacts

Philip Budge, MD, PhD
principal investigator · Washington University School of Medicine
Catherine Bjerum, MD, MPH
principal investigator · Case Western Reserve University
Toki Pascal Gabo, MD
principal investigator · Regional Hospital of Agboville, Southern Cote d'Ivoire
Benjamin Koudou, PhD
principal investigator · Regional Hospital of Agboville, Southern Cote d'Ivoire

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ivermectin · Diethylcarbamazine · Moxidectin

Start the discussion